Pre-Open Stock Movers 09/30: (LXK) (AUPH) (DB) Higher; (OPHT) (CAMP) (CTSH) Lower (more...)
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Lexmark (NYSE: LXK) 14% HIGHER; disclosed CFIUS approval for the Apex deal
Ophthotech Corp (NASDAQ: OPHT) 13.1% LOWER; down after Regeneron (NASDAQ: REGN) announced that Rinucumab (anti-PDGF-beta) co-formulated with Eylea (aflibercept) did not show any benefit over Eylea alone in the treatment of wet age-related macular degeneration (wAMD). Leerink defended.
Calamp Corp. (NASDAQ: CAMP) 12.9% LOWER; reported Q2 EPS of $0.27, in-line with the analyst estimate of $0.27. Revenue for the quarter came in at $90.5 million versus the consensus estimate of $92.26 million. GUIDANCE: Calamp Corp. sees Q3 2017 EPS of $0.24-$0.30, versus the consensus of $0.31.
Arbutus Biopharma Corporation (Nasdaq: ABUS) 10.4% LOWER; reported interim results from the first two cohorts of the ongoing ARB-1467 Phase II multi-dose clinical trial in chronically infected HBV patients. The first two cohorts enrolled patients with hepatitis B e-antigen (HBeAg) negative chronic HBV infection. At this time, serum HBsAg data are available following single doses for both Cohort 1 and Cohort 2 and following multiple doses for Cohort 1.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) 9.9% HIGHER; announced that in addition to voclosporin (23.7 mg BID) achieving its primary endpoint of Complete Remission (CR) at 24 weeks, both doses of voclosporin when added to the current standard of care of Mycophenolate Mofetil (MMF) and a forced oral corticosteroid taper have met all 24-week pre-specified secondary endpoints vs the control group. These pre-specified endpoints include: Partial Remission (PR), which is measured by a ≥50% reduction in UPCR with no concomitant use of rescue medication; time to CR and PR; reduction in Systemic Lupus Erythematosus Disease Activity Index or SLEDAI score; and reduction in UPCR over the 24-week treatment period.
Superior Drilling Products, Inc. (NYSE: SDPI) 9.4% LOWER; announced today the pricing of its underwritten registered offering of 5,000,000 shares of common stock at a price to the public of $1.00 per share
Cognizant (Nasdaq: CTSH) 8.2% LOWER; Says Conducting Internal Investigation Over Potential FCPA Violations
Mentor Graphics (NASDAQ: MENT) 5.6% HIGHER; Elliott show 8.1% stake.
Deutsche Bank (NYSE: DB) 5.4% HIGHER; bouncing from its recent tumble, including yesterday's 6.7% slide on worries some hedge funds are pulling back exposure. The company has been trying to reassure employees and the market that it is still sound.
Cempra, Inc. (Nasdaq: CEMP) 4.8% HIGHER; announced interim results showing anti-NASH effects in the first six nonalcoholic steatohepatitis (NASH) patients dosed with solithromycin in a Phase 2 study.
Sprouts Farmers Market (NASDAQ: SFM) 3.8% HIGHER; Jefferies upgraded from Hold to Buy with a price target of $24.00
NXP Semiconductors (NASDAQ: NXPI) 3.4% HIGHER; adds to gains on takeover reports.
Extended Stay America (NYSE: STAY) 3.1% LOWER; Extended Stay America, Inc. and ESH Hospitality, Inc. announced the pricing of the underwritten secondary offering (the offering) of 13,000,000 Paired Shares, each Paired Share consisting of a share of common stock of Extended Stay America, Inc. and a share of Class B common stock of ESH Hospitality, Inc., which are attached and trade together as Paired Shares. The Paired Shares were offered by certain selling stockholders affiliated with Centerbridge Partners, L.P., Paulson & Co. Inc. and The Blackstone Group L.P. (the Selling Stockholders) and were sold at a price to the public of $14.25 per share. The offering is expected to close on October 4, 2016, subject to customary closing conditions.
Skechers USA (NYSE: SKX) 2.2% HIGHER; Susquehanna upgraded from Neutral to Positive with a price target of $27.00
McCormick & Co. (NYSE: MKC) 2% HIGHER; reported Q3 EPS of $1.03, $0.09 better than the analyst estimate of $0.94. Revenue for the quarter came in at $1.09 billion versus the consensus estimate of $1.09 billion. McCormick & Co. sees FY2016 EPS of $3.75-$3.79, versus prior guidance of $3.68-$3.75 and the consensus of $3.75.
Costco Wholesale (NASDAQ: COST) 1.8% HIGHER; reported Q4 EPS of $1.77, $0.04 better than the analyst estimate of $1.73. Revenue for the quarter came in at $35.73 billion versus the consensus estimate of $36.81 billion. Comps rose 3%.
Wal-Mart (NYSE: WMT) 0.5% HIGHER; KeyBanc initiated coverage with an Overweight rating and a price target of $90
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pre-Open Stock Movers 01/18: (CLCD) (SHLO) (JAZZ) Higher; (GIMO) (TGT) (CSX) Lower (more...)
- Pre-Open Stock Movers 01/17: (FWP) (CLSN) (GEVO) Higher; (ADHD) (CBK) (UEC) Lower (more...)
- Biocept (BIOC) Adds to Gains Following Blue Cross Blue Shield of Texas News
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesDeutsche Bank, KeyBanc, Jefferies & Co, Paulson & Co. (PCI), Susquehanna International Group of Companies, Pre-Open Losers, Pre-Open Winners, Pre Market Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!